T
AUPH icon

TOBAM’s Aurinia Pharmaceuticals AUPH Stock Holding History

TOBAM’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-224,033
Closed -$3.09M – 429
2020
Q4 		$3.09M Buy
224,033
+18,661
+9% +$272K 0.14% 101
2020
Q3 		$3.02M Buy
205,372
+33,668
+20% +$488K 0.15% 98
2020
Q2 		$2.78M Buy
+171,704
New +$2.75M 0.18% 90

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TOBAM's AUPH Position: Q1 2021 in Review

TOBAM sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2021, closing a stake of 224,033 shares — an estimated $3.09M sold.

TOBAM first reported a position in AUPH in Q2 2020 and held it in 3 quarters. The position peaked at $3.09M in Q4 2020. 170 funds tracked by Wall St. Rank hold AUPH as of Q1 2021.

  • TOBAM reported no remaining Aurinia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • TOBAM sold 224,033 Aurinia Pharmaceuticals shares in Q1 2021, an estimated $3.09M.
  • TOBAM first reported a position in Aurinia Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • TOBAM's Aurinia Pharmaceuticals position peaked at $3.09M in Q4 2020.
  • 170 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2021.

Based on TOBAM's 13F filing for Q1 2021, filed 11 May 2021.